Literature DB >> 16849766

Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer.

Robin Matsuyama1, Sashidhar Reddy, Thomas J Smith.   

Abstract

PURPOSE: The number of patients receiving chemotherapy near the end of life is increasing, as are concerns about goals of treatment, toxicity, and costs. We sought to determine the available sources of knowledge, the choices, and concerns of actual patients, and how patients balanced competing issues.
METHODS: We used a literature search from 1980 to present.
RESULTS: Available patient sources provide little information about prognosis, choices, alternatives, consequences, or how to choose. Many patients would choose chemotherapy for a small benefit in health outcomes, and for a smaller benefit than perceived by their health care providers for their own treatment. Adverse effects are less a concern for patients than for their well health care providers. There are no decision aids to assist patients with metastatic disease in making their choices, such as there are for adjuvant breast therapy.
CONCLUSION: The perspective of the patient is different from that of a well person. Patients are willing to undergo treatments that have small benefits with major toxicity. Receiving realistic information about the different options of care and the likelihood of successful treatment or adverse effects is difficult. These factors may explain some of the increased use of chemotherapy near the end of life. Decision aids and honest, unbiased sources to inform patients of their prognosis, choices, consequences, typical outcomes, and ways to make decisions are needed. More prospective information about how patients make their choices, and what they would consider a good choice, would assist informed decision making.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849766     DOI: 10.1200/JCO.2005.03.6236

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  108 in total

1.  When doctors and patients disagree about medical futility.

Authors:  Mary S McCabe; Courtney Storm
Journal:  J Oncol Pract       Date:  2008-07       Impact factor: 3.840

2.  The debate in hospice care.

Authors: 
Journal:  J Oncol Pract       Date:  2008-05       Impact factor: 3.840

3.  Time, clinic technologies, and the making of reflexive longevity: the cultural work of time left in an ageing society.

Authors:  Sharon R Kaufman
Journal:  Sociol Health Illn       Date:  2010-02-01

4.  Chemotherapy in patients with advanced pancreatic cancer: too close to death?

Authors:  M Frigeri; S De Dosso; O Castillo-Fernandez; K Feuerlein; H Neuenschwander; P Saletti
Journal:  Support Care Cancer       Date:  2012-06-01       Impact factor: 3.603

Review 5.  Chemotherapy at end-of-life: an integration of oncology and palliative team.

Authors:  Wing-lok Chan; Ka-on Lam; Wai-kwan Siu; Kwok-keung Yuen
Journal:  Support Care Cancer       Date:  2015-11-25       Impact factor: 3.603

Review 6.  The value of progression-free survival to patients with advanced-stage cancer.

Authors:  Lesley J Fallowfield; Anne Fleissig
Journal:  Nat Rev Clin Oncol       Date:  2011-10-18       Impact factor: 66.675

7.  Understanding patient perspectives on communication about the cost of cancer care: a review of the literature.

Authors:  Erin W Hofstatter
Journal:  J Oncol Pract       Date:  2010-06-22       Impact factor: 3.840

8.  Commentary: "the Lake Wobegon effect, a natural human tendency to overestimate one's capabilities" (Wikipedia).

Authors:  Thomas J Smith
Journal:  Milbank Q       Date:  2013-12       Impact factor: 4.911

9.  Use of chemotherapy at the end of life in a Portuguese oncology center.

Authors:  José Ferraz Gonçalves; Carmen Goyanes
Journal:  Support Care Cancer       Date:  2007-08-22       Impact factor: 3.603

Review 10.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.